Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Lübbert

Showing results (101-110 of 119) with videos related to

Pageof 12
Sort By:
Leukemia|November 5, 2013
Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patientsU Platzbecker, H K Al-Ali, N Gattermann, et al.
Leukemia|January 17, 2017
Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study GroupN Jahn, M Agrawal, L Bullinger, et al.
Leukemia Research|June 30, 2015
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromesG Caocci, M T Voso, E Angelucci, et al.
Leukemia|June 22, 2013
Monosomal karyotype in MDS: explaining the poor prognosis?J Schanz, H Tüchler, F Solé, et al.
Leukemia|February 1, 2017
Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failureM Wattad, D Weber, K Döhner, et al.
Leukemia|January 23, 2024
The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classificationK Nachtkamp, C Strupp, M Vukelja, et al.
Leukemia|November 25, 2016
Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesisF Thol, S Klesse, L Köhler, et al.
Leukemia|May 3, 2016
Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS)M Mossner, J-C Jann, D Nowak, et al.
Leukemia|July 5, 2016
Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study groupF Theis, A Corbacioglu, V I Gaidzik, et al.
Leukemia|February 1, 2012
Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter studyU Germing, M Lauseker, B Hildebrandt, et al.
Pageof 12

Showing results (101-110 of 119) with videos related to

Sort By:
Pageof 12
Leukemia|November 5, 2013
Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patientsU Platzbecker, H K Al-Ali, N Gattermann, et al.
Leukemia|January 17, 2017
Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study GroupN Jahn, M Agrawal, L Bullinger, et al.
Leukemia Research|June 30, 2015
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromesG Caocci, M T Voso, E Angelucci, et al.
Leukemia|June 22, 2013
Monosomal karyotype in MDS: explaining the poor prognosis?J Schanz, H Tüchler, F Solé, et al.
Leukemia|February 1, 2017
Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failureM Wattad, D Weber, K Döhner, et al.
Leukemia|January 23, 2024
The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classificationK Nachtkamp, C Strupp, M Vukelja, et al.
Leukemia|November 25, 2016
Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesisF Thol, S Klesse, L Köhler, et al.
Leukemia|May 3, 2016
Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS)M Mossner, J-C Jann, D Nowak, et al.
Leukemia|July 5, 2016
Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study groupF Theis, A Corbacioglu, V I Gaidzik, et al.
Leukemia|February 1, 2012
Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter studyU Germing, M Lauseker, B Hildebrandt, et al.
Pageof 12